CD44 and familial pancreatic carcinoma: The nanoparticles were functionalized with a mAb against CD44, a cell surface marker of stem cells [63], and were capable of efficiently binding and killing pancreatic cancer stem cells in vitro and targeting an orthotopic model of pancreatic cancer in vivo.